Entresto market?

Do you mean the market size/sales, regulatory status, or competitive landscape for Entresto (sacubitril/valsartan)? Here’s a quick snapshot, and I can drill down to region or year if you want.

- What it is: Entresto is a first-in-class ARNI used to treat heart failure. Indications include:
- Adults with chronic heart failure with reduced ejection fraction (HFrEF) to reduce cardiovascular death and HF hospitalizations.
- Pediatric patients aged 1 year and older with symptomatic HF due to systolic dysfunction (per label).
- Market position: It’s a leading therapy in the heart failure space, widely adopted in the US, EU, and other major markets. It’s part of the standard of care for HFrEF and is often used alongside SGLT2 inhibitors.
- Market dynamics: Strong demand driven by guideline recommendations and expanding use; competition mainly from older, generic ACE inhibitors/ARBs, plus evolving HF treatment regimens that include SGLT2 inhibitors. Patent/price dynamics and potential generic competition in the future can influence long-term market share.
- Sales trend (high level): Entresto has been a multi-billion-dollar franchise since launch, with growth driven by broader adoption in more markets and new indications. Exact yearly sales vary by region and year.

If you tell me the specific region (e.g., United States, European Union, Asia-Pacific) and the year you care about, I can pull the latest sales figures and market size, plus any regulatory updates (e.g., label expansions or pediatric approvals).